Word on the Street

Analyst Actions: Agilent, Arena Pharmaceuticals


NEEDHAM CUTS ESTIMATES FOR AGILENT TECHNOLOGIES

Needham analyst John Harmon says the steep fall-off in Agilent Technologies' (A) January orders led to its first quarter shortfall.

Harmon says segment performance was mixed: Electronic Measurement revenues fell 23% (orders declined 28%); Bio-analytical saw orders up 2% organically, sales down 1%; Semiconductor and Board Test was the hardest hit, with orders down 66%, sales off 49%. He cuts $1.40 fiscal year 2009 (October) EPS estimate to $1.00 and $1.80 fiscal year 2010 forecast to $1.40.

Although end markets remain weak, and semiconductor board test is extremely anemic, Agilent possesses significant additional resources to align costs with revenues, he says. He keeps a hold opinion on the stock.

UBS FINANCIAL DOWNGRADES ARENA PHARMACEUTICALS TO NEUTRAL FROM BUY

UBS Financial analyst Jeff Elliott says he believes Arena Pharmaceuticals' (ARNA) current stock price represents a fair value for risk/reward of lorcaserin.

Although he remains positive on the expected outcome of the BLOOM and BLOSSOM trials, until final data is available, the potential for negative efficacy, safety results cannot be eliminated. He says the current tone at the FDA remains conservative, suggesting regulatory risk should not be overlooked.

Elliott raises $6 target to $7 to reflect shorter discount period and increased revenue multiple to reflect a stronger than expected out-licensing environment.

All of the views expressed in this research report accurately reflect the research analyst's personal views regarding any and all of the subject securities or issuers. No part of analyst compensation was, is or will be, directly or indirectly related to the specific recommendations or views expressed in this research report. Standard & Poor's Regulatory Disclosure

Any advice, analysis, or recommendations contained in articles labeled "Insight from Standard & Poor's" reflect the views of Standard & Poor's, which operates separately from and independently of BusinessWeek Online. It is possible that BWOL may from time to time publish information that is not consistent with advice, analysis, or recommendations that are published by Standard & Poor's. Standard & Poor's and BusinessWeek Online are each units of The McGraw-Hill Companies, Inc.


The Good Business Issue
LIMITED-TIME OFFER SUBSCRIBE NOW

Sponsored Financial Commentaries

Sponsored Links

Buy a link now!

 
blog comments powered by Disqus